Authors: Raja Padidela 1 , Moira S Cheung 2 , Vrinda Saraff 3 , and Poonam Dharmaraj 4

1 Royal Manchester Children’s Hospital and Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK 2 Evelina London Children’s Hospital, London, UK 3 Birmingham Women’s and Children’s Hospital, Birmingham, UK 4 Alder Hey Children’s NHS Foundation Trust, Liverpool, UK

Following approval and the availability of burosumab for management of children and adolescents with XLH, the British Paediatric and Adolescent Bone Group (BPABG), a comprehensive group of clinicians managing children with bone disorders in the UK, have taken an opportunity to provide recommendations for the management of XLH to optimise clinical practice.

You can read the paper in full here:

Citations and references can be made from the Endocrine Connections